Newsmakers: Isis Pharmaceuticals, Alliqua BioMedical, Health Net, Mesa Laboratories, ANI Pharmaceuticals Print E-mail
Monday, 03 November 2014 15:04

Stocks edged higher in afternoon trading Monday, with major indexes pushing deeper into record territory ahead of fresh economic updates this week.

The Dow Jones Industrial Average added eight points, or 0.1%, to 17398. The S&P 500 index gained six points, or 0.3%, to 2024. Both indexes set new intraday records, placing them on track for new closing highs for the

second straight session.

ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) earns a $5M milestone from GlaxoSmithKline (GSK -0.3%) for the designation of ISIS-GSK5rx as a development candidate for an undisclosed ocular disease. It is the

Error. Page cannot be displayed. Please contact your service provider for more details. (25)

second drug to be so identified in its collaboration with GSK. It earned a $1M milestone in July for a drug candidate to treat hepatitis B infection.

The Centers for Medicare and Medicaid Services (CMS) assigns a new reimbursement code to Alliqua Inc. (NASDAQ:ALQA) Biovance Human Amniotic Membrane Allograft, Q4154, that applies to products used outside of a physician's office. The code, categorized as Level II, expands reimbursement in the

outpatient setting and complements the Level 1 reimbursement code already in place.

Mesa Laboratories, Inc.(NASDAQ:MLAB) FQ2 results: Revenues: $18.5M (+45.7%); COGS: $7.4M (+45.1%); Operating Expenses: $6.2M (+21.6%); Operating Income: $4.9M (+96.0%); Net Income: $3.1M (+63.2%); EPS: $0.84 (+55.6%); Quick Assets: $3.7M (-33.9%).

Health Net, Inc.(NYSE:HNT) Q3 results: Revenues: $3,789.9M (+36.6%); Operating Expenses: $3,767.1M (+41.3%); Operating Income: $22.7M (-79.1%); Net Loss: ($8.9M) (-113.3%); Loss Per Share: ($0.11) (-113.3%); Quick Assets: $2779.4M (+22.6%); CF Ops: $588M (+94.6%).

ANI Pharmaceuticals Inc. (NASDAQ:ANIP) Q3 results: Revenues: $17.4M (+123.1%); COGS: $3.1M (+14.8%); R&D Expense: $0.9M (+80.0%); SG&A: $4.1M (+17.1%); Operating Income: $8.2M (+811.1%); Net Income: $6.7M (+458.3%); EPS: $0.59 (+353.8%); Quick Assets: $35.1M (+219.1%).




BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 
BMR:1